# Sacituzumab Govitecan in Metastatic Colorectal Cancer

> **NCT06243393** · PHASE2,PHASE3 · RECRUITING · sponsor: **University Hospital Heidelberg** · enrollment: 80 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Sacituzumab Govitecan (SG)
- **DRUG:** Physicians Choice (PhC).

## Key facts

- **NCT ID:** NCT06243393
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-19
- **Primary completion:** 2028-08-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06243393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06243393, "Sacituzumab Govitecan in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06243393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*